Literature DB >> 8396096

Preferential concentration of azithromycin in an infected mouse thigh model.

J A Retsema1, J M Bergeron, D Girard, W B Milisen, A E Girard.   

Abstract

The possibility of augmentation of azithromycin delivery to infection loci was evaluated by the use of Staphylococcus aureus thigh infection models with CD-1 mice. The intramuscular infections that developed were characterized by rapid growth of bacteria and induction of a localized oedema that was assessed gravimetrically. Microscopic examination of infected thighs showed massive infiltration of polymorphonuclear leucocytes (viable and degranulated), when compared to saline-injected thighs, from 24 to > or = 72 h after infection. Azithromycin concentrations were enhanced significantly (P < or = 0.02) in infected thigh tissues compared with contralateral non-infected tissues, and correlated with oedema from 24-72 h after challenge and dosing. The azithromycin levels in infected tissue after a 5 mg/kg dose were sufficient to cause a significant reduction in the number of cfu. If azithromycin administration was delayed until inflammation was more severe, the result was an even greater preferential concentration of azithromycin into the infected thigh. Preferential concentration of azithromycin was not observed when extensive oedema was produced by injection of histamine. However, this oedema was not associated with a significant influx of polymorphonuclear leucocytes. In comparative studies, macrolide antibiotics known to be concentrated in phagocytes, such as erythromycin, roxithromycin, and clarithromycin, were not concentrated preferentially in infected tissues under the experimental conditions used; tissue levels were above or at the in-vitro MIC level for < or = 24 h. The data indicate that delivery of biologically available azithromycin to infected tissues is enhanced by cellular inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396096     DOI: 10.1093/jac/31.suppl_e.5

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

Authors:  M H Nguyen; C J Clancy; Y C Yu; A S Lewin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

2.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

3.  Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo.

Authors:  J G den Hollander; J D Knudsen; J W Mouton; K Fuursted; N Frimodt-Møller; H A Verbrugh; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.

Authors:  A M Worm; A Osterlind
Journal:  Genitourin Med       Date:  1995-08

5.  Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  V Berry; C E Thorburn; S J Knott; G Woodnutt
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Intracellular activity of azithromycin against bacterial enteric pathogens.

Authors:  R M Rakita; K Jacques-Palaz; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers.

Authors:  C H Ballow; G W Amsden; V S Highet; A Forrest
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

8.  Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale.

Authors:  Constance D Rothermel
Journal:  Curr Ther Res Clin Exp       Date:  2003

9.  Distribution of systemic clarithromycin to gingiva.

Authors:  Renita C Burrell; John D Walters
Journal:  J Periodontol       Date:  2008-09       Impact factor: 6.993

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.